LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$3.03 – $3.39
Volume13,517
Market cap$30M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$30.43M
Price / earnings
—
Price / book
0.91×
Price / sales
—
EV / sales
—
EV / EBITDA
0.02×
Profitability
Earnings per share
-$15.01
Return on assets
-248.64%
Return on equity
-421.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.01×
Quick ratio
7.01×
Cash ratio
4.13×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LONA, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$6.58M
$6.88M
Research and development
$12.7M
$11.26M
Total operating expenses
$19.45M
$17.21M
Operating income
-$19.45M
-$17.21M
Interest expense
$0
$0
Income before taxes
-$19.01M
-$32.96M
Income taxes
$0
$0
Net income
-$19.01M
-$32.96M
Net income attributable to common shareholders
-$19.01M
-$32.96M
EBITDA
-$19.23M
-$16.98M
Basic earnings per share
-$0.80
-$1.73
Diluted earnings per share
-$0.80
-$1.73
Recent news
Company coverage with links to the original publishers.
LeonaBio, a clinical-stage biopharmaceutical company, announced its participation in two major industry conferences in June 2026. The company will present on its lead ALS candidate ATH-1105 at the ALS Drug Development Summit and participate in an oncology panel at the BIO International Convention. LeonaBio also announced board appointments of three new directors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.